Arkolith/Insider Trading/AKRO/Form 4

Gangloff Scott A.

Chief Technology OfficerAkero Therapeutics, Inc. (AKRO) · full profile →Form 4 · filed Dec 9, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
5
2 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 9, 2025Disposed to issuer(D)21K——0
Dec 9, 2025Disposed to issuer(D)5K——0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 9, 2025Disposed to issuer(D)18K——0
Dec 9, 2025Disposed to issuer(D)74K——0
Dec 9, 2025Disposed to issuer(D)205K——0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-25-312111) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML